HARMONi-GI1: 1L ivonescimab plus chemotherapy vs durvalumab plus chemotherapy for advanced BTC

Biliary tract cancers (BTCs) are rare epithelial tumors that arise in the bile ducts. Around 70% of patients with BTC are diagnosed at advanced stages, when surgery is no longer curative.1 Standard first-line (1L) treatment for advanced BTC (aBTC) combines immunotherapy with chemotherapy, where the TOPAZ-1 (NCT03875235) and KEYNOTE-966 (NCT04003636) trials demonstrated the benefit of adding durvalumab and pembrolizumab, respectively, to chemotherapy.1,2,3  The IMbrave151 (NCT04677504) trial of atezolizumab, a PD-L1-targeting immune checkpoint inhibitor (ICI), and bevacizumab, a VEGF-A inhibitor, in aBTC has also suggested a potential benefit from combining VEGF inhibitors with ICIs.1,4

The HARMONi-GI1 trial (NCT06591520), presented at the 2026 European Society for Medical Oncology (ESMO) Congress, investigated ivonescimab, a PD-1/VEGF bispecific antibody, in first-line aBTC. 682 patients, stratified by disease status and primary tumor location, were randomized 1:1 to receive ivonescimab plus chemotherapy or durvalumab plus chemotherapy, followed by maintenance ivonescimab or durvalumab, respectively. The primary endpoint was overall survival (OS) and key secondary endpoints were progression-free survival (PFS) and objective response rate (ORR).5

OS was significantly longer in the ivonescimab group than the durvalumab group (14.9 vs. 12.1 months; HR 0.75, 95% CI 0.61-0.92, P = 0.0031), as was PFS (8.4 vs. 5.8 months; HR 0.61, 95% CI 0.51-0.72, P <0.0001). ORR was similarly higher with ivonescimab at 53.8%, versus 32.5% with durvalumab. The safety profile of ivonescimab was manageable and the most common treatment-emergent adverse event was hematological toxicity. No new safety signals were reported for ivonescimab.5

James Harding, MD, Memorial Sloan Kettering Cancer Center, New York, NY, comments on the results and what they mean for the wider BTC treatment landscape:

“This study did show superiority of ivonescimab over durvalumab…I think it’s going to be related to longer follow-up [if this drug will ultimately be approved]. I think that if it were, it would represent a shift from PD-1 or PD-L1 to the bispecific.”

These results show that 1L ivonescimab plus chemotherapy significantly improved OS, PFS and ORR compared with the current standard of durvalumab plus chemotherapy in aBTC, with a manageable safety profile.


References

  1. Xu Q, Zhou S, Zhang C, et al. Ivonescimab plus gemcitabine and cisplatin as first-line therapy for advanced biliary tract cancer: A multicenter, open-label phase II trial. J Hepatol. 2026 Jul;S0168-8278(26)02682-6.
  2. Oh DY, He AR, Qin S, et al. Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer. NEJM Evid. 2022 Aug;1(8):EVIDoa2200015.
  3. Kelley RK, Ueno M, Yoo C, et al. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023 Jun;401(10391):1853-1865.
  4. El-Khoueiry AB, Ren Z, Chon H, et al. IMbrave151: A phase 2, randomized, double-blind, placebo-controlled study of atezolizumab with or without bevacizumab in combination with cisplatin plus gemcitabine in patients with untreated, advanced biliary tract cancer. J Clin Oncol. 2023 Feb;41(4_suppl):491.
  5. Zhou J, Zheng T, Fan J, et al. Ivonescimab plus chemotherapy versus durvalumab plus chemotherapy as first-line treatment for advanced biliary tract cancer: a randomized, controlled, double-blinded, phase 3 trial (HARMONi-GI1). Abstract LBA8. Presented at the ESMO Congress 2026; October 23–27, 2026; Madrid, Spain.